Radiopharmaceutical Clinical Trials in Latin America: A Logistics Playbook for Isotope-Dependent Studies

Radiopharmaceutical clinical trials are different. Even when the science is strong and the protocol is clean, programs can fail due to a reality that traditional device or drug teams underestimate: your investigational product expires—fast. That makes logistics, importation planning, and site readiness mission-critical.

Latin America offers compelling advantages for early-stage clinical research—experienced investigators, diverse patient populations, and often faster activation pathways. But isotope-dependent studies add unique constraints across borders, airports, customs processes, and nuclear medicine infrastructure. This article provides a sponsor-oriented playbook to design a radiopharmaceutical logistics system that supports protocol execution across Latin America.

1) Start with the “half-life reality” and build the trial around it

Radiopharmaceutical programs must align manufacturing, release, transport, and administration to the isotope’s half-life and imaging or therapeutic window. The practical implication is that clinical operations should be designed from the logistics backward—not from the protocol forward.

• Define the maximum allowable time (MAT): The maximum time from end-of-synthesis to administration that still meets dose and quality criteria.
• Translate MAT into route constraints: Which airports, flight schedules, and ground transport windows can reliably meet MAT?
• Choose sites accordingly: A great investigator is not enough if a site is two unreliable connections away from the arrival airport.

2) Build a supply strategy: local production, regional hubs, or cross-border shipment

Most sponsors consider three models, sometimes combined:

• Local production: Cyclotron or generator-based production inside the country, reducing border risk.
• Regional hub: Manufacturing in one country with shipments to nearby countries where timing is feasible.
• Cross-border shipment: Central manufacturing with direct shipment to sites, often higher operational risk for short half-life isotopes.

Decision drivers: isotope half-life, batch release requirements, frequency of dosing/imaging, customs reliability, and the maturity of nuclear medicine infrastructure.

3) Customs, permits, and paperwork: treat them as a core workstream

Unlike many conventional clinical programs, radiopharmaceutical shipments can require coordination across multiple authorities (health, customs, transport, and sometimes nuclear or radiation safety regulators). Paperwork failures are not “minor admin issues”—they can destroy a batch.

A practical sponsor approach:

• Create a country-specific import dossier: A standardized pack containing product description, safety documentation, shipping classification, and required permits.
• Pre-align with your logistics partner: Ensure they can manage controlled substances/radiation shipments and have airport-level handling experience.
• Plan for documentation constraints: Some submission systems impose file size and formatting limitations, which can impact how you structure supporting documents.

Risk mitigation: Maintain “pre-cleared” templates for invoices, certificates, and chain-of-custody records so each shipment is not a new negotiation.

4) Cold chain and handoffs: map every minute and every signature

Radiopharmaceutical trials require high integrity across handoffs—manufacturing release, airport handling, courier transfer, hospital receiving, radiopharmacy preparation (if applicable), and administration.

• Define temperature and shielding requirements: Include validated packaging and monitoring devices.
• Use chain-of-custody records: Document each transfer with time stamps and responsible parties.
• Plan for failed deliveries: What happens if a flight is canceled? If customs holds the shipment? If the site cannot dose a patient that day?

For short half-life isotopes, it may be more realistic to design protocols with flexible scheduling windows and backup dosing slots rather than a single “perfect” appointment that collapses with one delay.

5) Site readiness: nuclear medicine capability is necessary but not sufficient

Sites should be evaluated against operational capabilities that directly influence shipment success:

• Receiving readiness: Can the site receive shipments after hours? Who signs? Where is the secure holding area?
• Radiation safety workflow: Disposal, contamination procedures, monitoring, and staff training documentation.
• Imaging/therapy coordination: Scanner availability, staffing schedules, and patient flow.
• Contingency operations: Can the site reschedule quickly if dosing slips by hours?

Operational best practice: Run a “dry rehearsal” shipment to test handoffs, documentation, and receiving steps before the first patient.

6) Design a sponsor control tower for isotope-dependent trials

Because time is the critical resource, sponsors benefit from a simple control tower model:

• Shipment tracker: One dashboard for synthesis time, release, airport departure/arrival, customs status, courier pickup, and site receipt.
• Rapid decision protocol: A predefined decision tree for whether to proceed, reroute, or cancel based on delay thresholds.
• Communications cadence: Clear check-in times with manufacturing, courier, and site staff during dosing days.

This structure reduces last-minute improvisation and helps teams learn systematically from each shipment cycle.

FAQ: Radiopharmaceutical trial logistics in Latin America

1) What is the single biggest logistics risk for short half-life isotopes?

Border and airport unpredictability. A delay of hours can materially reduce dose viability, making preplanned routes and contingency options essential.

2) Should we prioritize local production even if it is more expensive?

Sometimes yes. Local production can reduce cross-border risk and improve dosing reliability, which may be more valuable than cost savings when early data is the goal.

3) How can sponsors reduce failed dosing days?

By selecting sites near reliable arrival points, rehearsing end-to-end shipments, maintaining documentation templates, and using a control tower to manage real-time decisions.

Conclusion: Radiopharmaceutical trials can be executed successfully in Latin America, but they require a logistics-first mindset. Build your protocol around half-life constraints, treat customs as a core workstream, and operate a shipment control tower. When logistics is engineered as a system—not handled as an afterthought—sponsors gain the reliability needed to generate high-quality clinical data on schedule.